Background: Two ESI-LC/MS/MS methods were validated for the quantitative analysis of loxapine, amoxapine, 7-OHloxapine, 8-OH-loxapine and loxapine N-oxide in human K2EDTA plasma. Cation-exchange solid phase extraction (SPE) was used to extract loxapine, amoxapine and the two hydroxylated metabolites, and organic precipitation was used to quantify loxapine N-oxide.
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Intensity, cps Numbers reported as accuracy ± precision (%CV) and represent the average of 5 days of analysis.
Conclusions: Both methods were used to successfully analyze human clinical plasma samples from subjects who received an inhalation delivery of loxapine in doses ranging from 0.625 to 10 mg. Both methods followed the latest FDA Guidance on Bioanalytical Method Validation. The validated method for the quantitation of loxapine N-oxide in human plasma was important because although it is an inactive metabolite, the measured levels indicate that it is the second most prevalent metabolite. See full publication for more details.
